ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: SA-PO1088

Post-Transplant Lymphoproliferative Disorders in Kidney Transplant Recipients: A Retrospective Single-Center Cohort Analysis

Session Information

Category: Transplantation

  • 2102 Transplantation: Clinical

Authors

  • Jan, Muhammad Yahya, Indiana University School of Medicine, Indianapolis, Indiana, United States
  • Kelly, Bethany, Indiana University School of Medicine, Indianapolis, Indiana, United States
  • Raza, Ahsan, Indiana University School of Medicine, Indianapolis, Indiana, United States
  • Adebiyi, Oluwafisayo O., Indiana University School of Medicine, Indianapolis, Indiana, United States
  • Yaqub, Muhammad S., Indiana University School of Medicine, Indianapolis, Indiana, United States
  • Sharfuddin, Asif A., Indiana University School of Medicine, Indianapolis, Indiana, United States
Background

To characterize the posttransplant lymphoproliferative disorders(PTLD) including the Epstein-Barr virus (EBV) status, histological subgroups, site of occurrence and the clinical outcomes of kidney transplant recipients at our institution.

Methods

A retrospective cohort study of all kidney transplant recipients who developed PTLD and were followed up at our transplant centers from 1999 through 2021.

Results

44 patients developed PTLD, with majority 86.4% being kidney alone transplants, while 13.6% were Kidney-Pancreas recipients. Heme-Oncology were primarily responsible for the treatments which was tailored to their individual type and stage and site of PTLD. Immunosuppression was lowered on an individualized basis.

Conclusion

We describe a large series of PTLD cases, with their outcomes with reasonable outcomes. The time-line to PTLD was not limited to early post-transplant course as seen in other series, and EBV-ve PTLD was more common. Careful adjustment of immunosuppression, early detection, and aggressive treatment can lead to acceptable outcomes.